Icon Early Phase Services

Recent papers from Icon Early Phase Services

1. Bioequivalence Between a Gantenerumab Disposable Syringe and an Autoinjector: A Randomized Controlled Trial in Healthy VolunteersClinical Pharmacology in Drug Development · 2026
2. Phase 1 Studies to Assess Inhaled Seralutinib as a Perpetrator or a Victim of Drug‐Drug Interactions in Healthy ParticipantsClinical Pharmacology in Drug Development · 2024
3. A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjectsClinical and Translational Science · 2022
4. Two‐Part Phase 1 Multiple‐Ascending‐Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy AdultsClinical Pharmacology in Drug Development · 2021
5. Intraosseous vascular access using the EZ-IO can be safely maintained in the adult proximal humerus and proximal tibia for up to 48 h: Report of a clinical studyThe Journal of Vascular Access · 2021
6. A First‐in‐Human Clinical Study With TRV734, an Orally Bioavailable G‐Protein–Biased Ligand at the μ‐Opioid ReceptorClinical Pharmacology in Drug Development · 2019
7. A Randomized, Placebo‐Controlled, Multiple‐Ascending‐Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy SubjectsClinical Pharmacology in Drug Development · 2018
8. A Novel Method for Rapid Bedside Measurement of GFRJournal of the American Society of Nephrology · 2018
9. Does GLP-1 suppress its own basal secretion?Endocrine Research · 2015